{"id":"W2132196134","doi":"10.1186/1475-2840-13-26","title":"Residual macrovascular risk in 2013: what have we learned?","year":2014,"lang":"en","type":"review","venue":"Cardiovascular Diabetology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; Montreal Clinical Research Institute; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"H. Lundbeck A/S; Servier; Astellas Pharma; Novo Nordisk; International Atherosclerosis Society; Québec Consortium for Drug Discovery; Anthera; Regeneron Pharmaceuticals; Amarin Corporation; Boston Scientific Corporation; Genentech; Valeant Pharmaceuticals International; Daiichi Sankyo Europe; Kowa Company; Halozyme; Sanofi; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Amylin Pharmaceuticals; Amgen; Pfizer","keywords":"Ezetimibe; Medicine; Residual risk; PCSK9; Metabolic syndrome; Internal medicine; Statin; Niacin; Type 2 diabetes; Diabetes mellitus; Endocrinology; Intensive care medicine; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008605957,0.001164684,0.002894266,0.002348139,0.001690586,0.006864857,0.00307354,0.006564498,0.01745969],"category_scores_gemma":[0.0332551,0.0005481001,0.002100136,0.002160361,0.002160439,0.00916834,0.003324704,0.01105221,0.004660847],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004674318,"about_ca_system_score_gemma":0.0152408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03476189,"about_ca_topic_score_gemma":0.04042425,"domain_scores_codex":[0.9973531,0.0007572941,0.0003778969,0.0004328958,0.0006216216,0.0004573032],"domain_scores_gemma":[0.978599,0.006447927,0.001046634,0.000611482,0.008668938,0.004625989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003749929,0.0001698725,0.006029608,0.007379219,0.0002870227,0.0002632708,0.0004185762,0.0002932574,0.00008804748,0.006558452,0.3365624,0.6415753],"study_design_scores_gemma":[0.0002743458,0.0004709106,0.02928756,0.06695654,0.0008576168,0.001141529,0.004809852,0.001034164,0.0002765756,0.02779841,0.8667934,0.0002990923],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001927434,0.6030621,0.0009631469,0.3580332,0.02917432,0.00006283052,0.001649336,0.0002750097,0.004852586],"genre_scores_gemma":[0.02177713,0.7714845,0.003716302,0.1629843,0.03302179,0.0002120149,0.002751077,0.0001459101,0.003907027],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03476189,"threshold_uncertainty_score":0.0691191,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03707531681915845,"score_gpt":0.3160759821856446,"score_spread":0.2790006653664862,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}